Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT05368207
NA
Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
Sponsor: University Health Network, Toronto
View on ClinicalTrials.gov
Summary
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Official title: Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
1
Start Date
2021-12-06
Completion Date
2025-10-16
Last Updated
2026-06-23
Healthy Volunteers
No
Interventions
DRUG
Pembrolizumab
Pembrolizumab is an antineoplastic agent, monoclonal antibody against PD-L1.
Locations (1)
Princess Margaret Cancer Centre
Toronto, Ontario, Canada